According to CIDRAP
The World Health Organization (WHO) has introduced a new global blueprint designed to help countries strengthen their response to fungal diseases and the growing threat of antifungal resistance. The framework comes as health authorities report that fungal infections affect more than 300 million people worldwide each year, yet they remain widely under-recognized, underdiagnosed, and inadequately managed. The WHO warns that increasing antifungal resistance, combined with limited treatment options and insufficient diagnostic capacity, is making fungal diseases an increasingly significant public health challenge. The organization hopes the blueprint will encourage governments to incorporate fungal diseases into national health strategies and antimicrobial resistance (AMR) action plans.
The Blueprint for Strengthening Responses to Fungal Disease and Antifungal Resistance, published on 30 June 2026, identifies four strategic priorities for national health systems, organized around what WHO describes as interconnected domains: public health and health system interventions; therapies, technologies and innovation systems; laboratory systems, surveillance and outbreak preparedness; and social, environmental and One Health drivers. These include improving awareness, preparedness, and emergency response; expanding equitable access to reliable diagnostics and effective antifungal medicines; strengthening laboratory capacity and surveillance networks to detect fungal infections and monitor resistance; and addressing the environmental, agricultural, and social factors that contribute to the emergence and spread of fungal diseases. WHO also emphasizes the importance of increasing investment in research to accelerate the development of new antifungal drugs, rapid diagnostic tools, and preventive strategies, as only a limited number of antifungal drug classes — just five new classes developed in the past 75 years — are currently available for clinical use.
The report highlights several fungal pathogens that present particular concern, including Candida auris, Aspergillus fumigatus, Cryptococcus neoformans, Candida albicans, and Candida glabrata — the first four of which WHO designated “critical priority” pathogens in its original 2022 Fungal Priority Pathogens List, which identified 19 fungal pathogens or pathogen groups requiring urgent research, development, and public health action. Among them, Candida auris has become one of the world’s most closely monitored multidrug-resistant fungi because it spreads efficiently in healthcare facilities and can survive on environmental surfaces. Recent surveillance data from the United States also indicate that reported clinical cases of Candida auris have increased substantially over the past several years — from 2,882 cases in 2022 to 6,197 in 2024, according to CDC surveillance — reinforcing concerns about ongoing transmission in hospitals and long-term care facilities. WHO notes that climate change, expanding international travel, increased numbers of immunocompromised patients, and the widespread use of antifungal compounds in agriculture may all contribute to the growing burden of antifungal resistance.
Health experts stress that invasive fungal infections disproportionately affect individuals with weakened immune systems, including patients undergoing cancer treatment, organ transplant recipients, people living with HIV, and those with chronic lung disease. However, WHO also notes that serious fungal infections can occur in immunocompetent individuals when diagnosis is delayed or effective antifungal treatment is unavailable. Low- and middle-income countries remain particularly vulnerable because of limited laboratory infrastructure, restricted access to diagnostics and medicines, and broader socioeconomic challenges. Through its new blueprint, WHO aims to provide countries with a practical roadmap for improving surveillance, strengthening healthcare systems, expanding access to treatment, and reducing preventable deaths associated with fungal diseases and antifungal resistance.
References
UN News (2026). New WHO plan urges stronger action against fungal disease.
According to CIDRAP
Key Takeaways
- The World Health Organization (WHO) has introduced a new global blueprint designed to help countries strengthen their response to fungal diseases and the growing threat of antifungal resistance.
- The framework comes as health authorities report that fungal infections affect more than 300 million people worldwide each year, yet they remain widely under-recognized, underdiagnosed, and inadequately managed.
- The organization hopes the blueprint will encourage governments to incorporate fungal diseases into national health strategies and antimicrobial resistance (AMR) action plans.
- However, WHO also notes that serious fungal infections can occur in immunocompetent individuals when diagnosis is delayed or effective antifungal treatment is unavailable.
- Blueprint for Strengthening Responses to Fungal Disease and Antifungal Resistance.
Frequently Asked Questions
What is the WHO’s global blueprint for combating fungal diseases?
The World Health Organization (WHO) has introduced a new global blueprint designed to help countries strengthen their response to fungal diseases and the growing threat of antifungal resistance. The framework comes as health authorities report that fungal infections affect more than 300 million peop
How does antifungal resistance pose a threat to global health?
The Blueprint for Strengthening Responses to Fungal Disease and Antifungal Resistance, published on 30 June 2026, identifies four strategic priorities for national health systems, organized around what WHO describes as interconnected domains: public health and health system interventions; therapies,
What global strategies are being developed to address fungal infections?
The report highlights several fungal pathogens that present particular concern, including Candida auris, Aspergillus fumigatus, Cryptococcus neoformans, Candida albicans, and Candida glabrata — the first four of which WHO designated “critical priority” pathogens in its original 2022 Fung
What are the main risks associated with WHO Releases Global Blueprint?
Health experts stress that invasive fungal infections disproportionately affect individuals with weakened immune systems, including patients undergoing cancer treatment, organ transplant recipients, people living with HIV, and those with chronic lung disease. However, WHO also notes that serious fun
What actions are recommended regarding WHO Releases Global Blueprint?
World Health Organization (2026). Blueprint for Strengthening Responses to Fungal Disease and Antifungal Resistance.
